Evidence map›Paper›PMID 26926626›Full record

ArticleAntimicrobial agents and chemotherapy2016

Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats. 4. Aztreonam.

Sandrine Marchand, Nicolas Grégoire, Julien Brillault, Isabelle Lamarche, Patrice Gobin, William Couet

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Biopharmaceutical profiling of anti-infective sanggenons fromInternational journal of pharmaceutics: X · 2024
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sandrine MarchandInserm U1070, Pôle Biologie Santé, Poitiers, France Université de Poitiers, UFR Médecine-Pharmacie, Poitiers, France CHU Poitiers, Service de Toxicologie-Pharmacocinétique, Poitiers, France sandrine.marchand@univ-poitiers.fr.
Nicolas GrégoireInserm U1070, Pôle Biologie Santé, Poitiers, France Université de Poitiers, UFR Médecine-Pharmacie, Poitiers, France.
Julien BrillaultInserm U1070, Pôle Biologie Santé, Poitiers, France Université de Poitiers, UFR Médecine-Pharmacie, Poitiers, France.
Isabelle LamarcheInserm U1070, Pôle Biologie Santé, Poitiers, France Université de Poitiers, UFR Médecine-Pharmacie, Poitiers, France.
Patrice GobinInserm U1070, Pôle Biologie Santé, Poitiers, France CHU Poitiers, Service de Toxicologie-Pharmacocinétique, Poitiers, France.
William CouetInserm U1070, Pôle Biologie Santé, Poitiers, France Université de Poitiers, UFR Médecine-Pharmacie, Poitiers, France CHU Poitiers, Service de Toxicologie-Pharmacocinétique, Poitiers, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to determine aztreonam (ATM) membrane permeability using Calu-3 cells and its plasma and pulmonary epithelial lining fluid (ELF) pharmacokinetics in rats after intratracheal nebulization and intravenous administration (15 mg · kg(-1)). ATM exhibits low Calu-3 permeability (0.07 ± 0.02 × 10(-6) cm · s(-1)), and a high area under the ELF/unbound plasma concentration time curve between 0 and infinity (AUCELF/AUCu,plasma) ratio of 1,069 was observed after nebulization in rats. These results confirm that ATM is a low-permeability molecule and a good candidate for nebulization.

Indexed as

Administration, InhalationAnimalsAnti-Bacterial AgentsAnti-Infective AgentsAztreonamLungMaleRatsRats, Sprague-DawleyAnti-Bacterial AgentsAnti-Infective AgentsAztreonam

Identifiers

PMID26926626
PMCPMC4862445

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.